Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;204(3):892-897.
doi: 10.1111/bjh.19217. Epub 2023 Nov 27.

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic

Sandra Castaño-Díez  1   2   3 , Helena Pomares  4 , Daniel Esteban  1 , Francesca Guijarro  3   5 , Carlos Jiménez-Vicente  1   2 , Inés Zugasti  1 , José Ramón Álamo  5 , Víctor Torrecillas Mayayo  2 , Mònica López-Guerra  3   5   6 , Cristina de la Fuente  7 , Paola Charry  8 , Albert Cortés-Bullich  1 , Álex Bataller  1   2   3   9 , Clara Maluquer  4 , Dolors Colomer  3   5   6 , María Rozman  3   5 , Montserrat Arnan  4 , Blanca Xicoy  7   9 , Jordi Esteve  1   2   3   9 , Marina Díaz-Beyá  1   3   9
Affiliations

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic

Sandra Castaño-Díez et al. Br J Haematol. 2024 Mar.

Abstract

Recently modified diagnostic criteria for chronic myelomonocytic leukaemia (CMML) have lowered the cut-off for absolute monocytosis. In the largest series to date, we have analysed 313 CMML patients, including 104 with oligomonocytic (OM)-CMML. Five-year survival was longer for OM-CMML than for other patients (p < 0.001). Multivariate analysis identified OM-CMML as a favourable prognostic factor (HR 0.58; p = 0.002). The 5-year cumulative incidence of progression to classical CMML was 47%. Older age and transfusion dependence were adverse prognostic factors for OM-CMML. Our results support the inclusion of OM-CMML in the CMML category as a subtype with superior outcomes.

Keywords: CMML; chronic myelomonocytic leukaemia; oligomonocytic.

PubMed Disclaimer

Conflict of interest statement

J.E.: consultancy-honoraria (AbbVie, Novartis, Astellas Pharma, Jazz Pharmaceuticals, BMS-Celgene, Pfizer and Daichii-Sankyo), research grants (Novartis and Jazz Pharmaceuticals); M.D.B.: consultant or advisory role, travel grants or speaker (Bristol Myers Squibb, AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Takeda Pharmaceuticals, Novartis). The funders had no role in the design of the study; in the collection, analyses or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

References

REFERENCES

    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200-1228.
    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
    1. Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, et al. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017;30(9):1213-1222.
    1. Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, et al. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. Leuk Res. 2018;65:1-4.
    1. Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019;104(10):1935-1949.

Publication types